Drug Trial Radar · NCT06703255
A Phase 2 Study of HX301 in Patients with High-grade Giloma
Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Jan 8, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Hangzhou Hanx Biopharmaceuticals, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will include a dose-escalation and dose-expansion component to establish the recommended Phase 2 dose (RP2D) for HX301 in combination with Temozolomide and to evaluate the preliminary antitumor activity of HX301.HX301 is an investigational drug that has not yet been approved by the Food and Drug Administration (FDA) or any other regulatory authorities for commercial purposes.
Conditions
- Glioma
Interventions
HX301+/TemozolomideDrug
Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional "3 + 3" rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part I: Number of participants experiencing Adverse Events (AEs)Time frame: All AEs up to 28(±7)days after the last dose of study treatment
- Part I: Identify the recommended phase IIa dose (RP2D) of HX301 in patients with high-grade glioma;Time frame: 24 Cycles of 28 days each.
- Part II (HX301 monotherapy safety run-in period) : Number of participants experiencing Adverse Events (AEs)Time frame: All AEs up to 28(±7)days after the last dose of study treatment
- Part II (HX301 monotherapy safety run-in period) : Identify the recommended phase IIa dose (RP2D) of HX301 combination with TMZ in patients with high-grade glioma;Time frame: 24 Cycles of 28 days each.
- Part II (HX301 in combination with temozolomide) : Progression-free survival(PFS) per Investigator assessed using RANO criteria.Time frame: 24 Cycles of 28 days each.
- Part II (HX301 in combination with temozolomide) :Objective response rate(ORR) per Investigator assessed using RANO criteria.Time frame: 24 Cycles of 28 days each.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.